Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $18.8 million.

  • Anika Therapeutics' Operating Expenses fell 344.81% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year increase of 6724.78%. This contributed to the annual value of $81.1 million for FY2024, which is 72.1% down from last year.
  • As of Q3 2025, Anika Therapeutics' Operating Expenses stood at $18.8 million, which was down 344.81% from $18.5 million recorded in Q2 2025.
  • Anika Therapeutics' Operating Expenses' 5-year high stood at $35.4 million during Q1 2023, with a 5-year trough of -$18.9 million in Q4 2023.
  • For the 5-year period, Anika Therapeutics' Operating Expenses averaged around $19.4 million, with its median value being $21.5 million (2024).
  • Per our database at Business Quant, Anika Therapeutics' Operating Expenses tumbled by 14632.94% in 2022 and then skyrocketed by 19419.94% in 2024.
  • Anika Therapeutics' Operating Expenses (Quarter) stood at $27.3 million in 2021, then tumbled by 146.33% to -$12.6 million in 2022, then tumbled by 49.9% to -$18.9 million in 2023, then surged by 194.2% to $17.8 million in 2024, then increased by 5.53% to $18.8 million in 2025.
  • Its Operating Expenses stands at $18.8 million for Q3 2025, versus $18.5 million for Q2 2025 and $19.0 million for Q1 2025.